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Is Patent Protection an Incentive 
for Innovation?




1- Why this topic ? 
Controversies about the effects of patents on 
Innovation
2- Why Pharmaceuticals ?
Patentability of pharmaceuticals
3- Why Tunisia ?
Pharmaceutical patents since January 2005
Emphasis on the production of generics
Main Question
What Impacts Would Patents 
have on the Pharmaceutical 
Innovation in Tunisia ?
Axes of the Presentation
1. The pharmaceutical industry in Tunisia, the 
focus on the production of generics
2. Advantages and limits of a pharmaceutical 
industry based on the production of generics
3. The role of patent protection in promoting 
the pharmaceutical innovation in Tunisia
Definition
Generics
 Copies of the brand-name drug whose 
patent expired (20 years)
 WHO: Tight control => generics have the 
same quality as the brand-name drugs
 Much less expensive <= they are free from 
expenditures in R&D
Axes of the Presentation
1.   The pharmaceutical industry in Tunisia, 
the focus on the production of generics
2.   Advantages and limits of a pharmaceutical 
industry based on the production of 
generics
3.   The role of patent protection in promoting 
the pharmaceutical innovation in Tunisia






Ministry of Public Health, 2008
Pharmaceutical Laboratories in Tunisia
30 pharmaceutical firms
The Pharmaceutical Industry 
in Tunisia








Ministry of Public Health, 2008
The Local Production
 49% licensed drugs
 51% generics







The Distribution Network of Pharmaceuticals 
in Tunisia
Foreign Suppliers







Increase the share of the local production 
Improve the production of  generics
Encouraging Measures for Generics
After the last reform of the social security 
system (2007), the National Fund of Health 
Insurance reimburses patients on the basis of 
the least expensive therapeutic equivalent
Enhance the market demand for generics
Axes of the Presentation
1. The pharmaceutical industry in Tunisia, the 
focus on the production of generics
2. Advantages and limits of a pharmaceutical 
industry based on the production of 
generics
3. The role of patent protection in promoting 
the pharmaceutical innovation in Tunisia
Benefits in terms of Costs
Control drugs’ prices 
Reduce health expenditures 
Accessible drugs to lower-income 
patients
 Local production of generics contributes at 
saving currency
(very important goal for Tunisia after the continuous appreciation 
of the Euro against the Dinar)
Benefits for the Local Industry
 Consolidate the local industrial tissue
 Reduce unemployment
 Increase exports => ameliorate the trade balance
 Attract multinational firms and benefit from FDI in 
terms of technological transfer, employment, …
 Generics producers preserve their independency
Limits
 Local firms are also dependent to foreign 
laboratories (just copies)
 Local firms submit to a period of “inertia” equal 
to the patent life of the brand name drug           
bad effects when dealing with dangerous 
diseases
 Spread a sort of “passiveness” instead of 
enhancing the sense of creativeness and 
inventiveness
What Role do Patents Play ?
Axes of the Presentation
1. The pharmaceutical industry in Tunisia, the 
focus on the production of generics
2. Advantages and limits of a pharmaceutical 
industry based on the production of 
generics
3. The role of patent protection in promoting 
the pharmaceutical innovation in Tunisia
An Encouraging Legal Framework
 Research units : 260 in 2005, 23% 
of them are laboratories of medical 
studies
 Exchanging program with foreign 
researchers in prior and strategic 
fields (energy, biotechnologies and 
health)
Human Resources
 School enrollment in higher education: 29% 
(2005) (12,2% Morocco, 15% Algeria)
 0,44% pharmacy students
 Few number of Tunisian pharmacy students 
carry out pharmaceutical researches in 
Tunisia
Immigration to developed 
countries (Europe)
Financial Resources
 600 million€, 2006  whole pharmaceutical sector
 Pharmaceutical R&D requires huge funds
 Special raw materials : very expensive + sometimes 
non available for some developing countries
Immigration to developed countries
Decrease in the innovation capabilities
Innovation Output Indicator Pharmaceutical






































National Institute of Standardization and Industrial Property (INNORPI, 2008)
Pharmaceutical Patents
Technological transfer => 
access to new technologies
-Promote local innovation spirit








-Increase prices of patented 
drugs
-Limit access of lower-income 
people to patented drugs
-Encourage the production of generics
- Promote exports of generics
-Attract FDI + employment
“Might”
To Conclude …
 In pharmacy education, put a more emphasis on 
applied researches
 Reduce bureaucracy and complicated administrative 
procedures facilitate access to information
 Alternative sources of financing (Cooperation with 
foreign firms + privatization)
 Keep encouraging the production of generics in 
order to assure the access of all patients to essential 
drugs  +  Combine the short term effects of generics 
with the long term effects of patents.
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